| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/24/2003 | CA2488802A1 Ophthalmic compositions for treating ocular hypertension |
| 12/24/2003 | CA2488752A1 Novel maxi-k channel blockers, methods of use and process for making the same |
| 12/24/2003 | CA2488705A1 A nanoporous particle with a retained target |
| 12/24/2003 | CA2488701A1 Reversed liquid crystalline phases with non-paraffin hydrophobes |
| 12/24/2003 | CA2488643A1 Coated particles, methods of making and using |
| 12/24/2003 | CA2488501A1 Nano-sized self-assembled structured liquids |
| 12/24/2003 | CA2488026A1 Powdery respiratory tonic composition |
| 12/24/2003 | CA2487809A1 Aptamer-toxin molecules and methods for using same |
| 12/24/2003 | CA2487514A1 Materials with both bioadhesive and biodegradable components |
| 12/24/2003 | CA2479309A1 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 12/24/2003 | CA2477878A1 Peptides selectively lethal to malignant and transformed mammalian cells |
| 12/23/2003 | US6667393 Azalide antibiotic compositions |
| 12/23/2003 | US6667371 Having hydrophilic and hydrophobic blocks; encapsulation or solubilization of water insoluble materials; sustained release encapsulation |
| 12/23/2003 | US6667344 Formoterol, or a derivative; long term storage stability |
| 12/23/2003 | US6667324 Dry blend pharmaceutical formulations |
| 12/23/2003 | US6667323 Dry-blend pharmaceutical formulations |
| 12/23/2003 | US6667321 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| 12/23/2003 | US6667293 Of certain phosphorothioate antisense oligonucleotides used to treat pathogenic infections, cancer, and inherited conditions |
| 12/23/2003 | US6667292 Metabolite is an s-nitroso-low molecular weight thiol compound, s-nitrosoglutathione; blood substitutes and organ perfusion solutions |
| 12/23/2003 | US6667156 Treating nervous system tumors; obtain cells, incubate with modulator, evaluate tumor propagtion |
| 12/23/2003 | US6667061 Microparticles comprising polymeric binder and injection vehicle, wherein microparticles are suspended in vehicle at concentration of greater than 30 mg/ml to form suspension having viscosity of 600 cp at 20 degrees C |
| 12/23/2003 | US6667060 Pregelatinized starch in a controlled release formulation |
| 12/23/2003 | US6667059 Odor-masking coating for a pharmaceutical preparation |
| 12/23/2003 | US6667058 Oral forms of administration containing solid flupirtine with controlled release of active substance |
| 12/23/2003 | US6667055 Filler binder for tablets |
| 12/23/2003 | US6667053 D and L etherlipid stereoisomers and liposomes |
| 12/23/2003 | US6667052 Drug delivery; diabete therapy; penetration enhancer mixture of protein and oxidizer |
| 12/23/2003 | US6667048 Pharmaceutical composition comprising taxoid, taxane or taxine as chemotherapeutic agent, alpha-tocopherol, tocopherol polyethylene glycol succinate, and aqueous phase, in form of emulsion or microemulsion with drug in oil phase |
| 12/23/2003 | US6667043 Technical di- and triglyceride mixtures |
| 12/23/2003 | US6667026 Allergic contact dermatitis treatment and composition therefor |
| 12/23/2003 | US6667024 Kit comprising molecule with radioisotope binding site linked to antigen-binding fragment of antibody that specifically binds to tumor associated antigen, and metal chelator and basic amino acid or peptide clearing agents |
| 12/23/2003 | CA2323211C Topical anesthetic formulation |
| 12/23/2003 | CA2302232C Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent |
| 12/23/2003 | CA2264394C Use of bilayer forming emulsifiers in nutritional compositions comprising divalent metal salts |
| 12/23/2003 | CA2147172C Transdermal therapeutic system for the release of 17-.beta.-estradiol and process for its production |
| 12/18/2003 | WO2003104432A2 Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins |
| 12/18/2003 | WO2003104402A2 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 12/18/2003 | WO2003104303A1 Polyaminoacids functionalized by alpha tocopherol and uses thereof, particular for therapeutic applications |
| 12/18/2003 | WO2003104282A2 Immunoadhesin comprising a glycoprotein vi domain |
| 12/18/2003 | WO2003104260A2 Pharmaceutical formulation |
| 12/18/2003 | WO2003104254A2 Novel derivatives of androstane and androstene with ascorbic a cid and use thereof in treating or preventing various conditions, diseases, and disorders |
| 12/18/2003 | WO2003103822A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 12/18/2003 | WO2003103723A2 Neutrophil imaging methods in cyctic fibrosis |
| 12/18/2003 | WO2003103718A2 Intracellular delivery of biological effectors |
| 12/18/2003 | WO2003103717A1 Therapeutic conjugate consisting of a mek inhibitor and a targeting agent |
| 12/18/2003 | WO2003103716A1 Polymeric based complex |
| 12/18/2003 | WO2003103715A1 Modified byrodin 1 with reduced immunogenicity |
| 12/18/2003 | WO2003103714A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same |
| 12/18/2003 | WO2003103691A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 12/18/2003 | WO2003103689A1 Molecular iodine pharmaceutical composition |
| 12/18/2003 | WO2003103687A1 Liquid formulation of decitabine and use of the same |
| 12/18/2003 | WO2003103685A1 A method of treating human skin and a skin care composition for use in such a method |
| 12/18/2003 | WO2003103681A2 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema |
| 12/18/2003 | WO2003103673A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 12/18/2003 | WO2003103662A2 Inhibitors of glycoprotein vi |
| 12/18/2003 | WO2003103644A2 Guanidino phenylalanin compounds used as urokinase inhibitors |
| 12/18/2003 | WO2003103641A1 Patch |
| 12/18/2003 | WO2003103640A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
| 12/18/2003 | WO2003103639A1 Chewable soft capsule |
| 12/18/2003 | WO2003103635A1 Extended release formulation of divalproex sodium |
| 12/18/2003 | WO2003103633A1 Nanoparticulate sterol formulations and sterol combinations |
| 12/18/2003 | WO2003103632A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| 12/18/2003 | WO2003103631A1 Novel high viscosity embolizing compositions comprising prepolymers |
| 12/18/2003 | WO2003103629A1 Orally disintegrating tablets and process for obtaining them. |
| 12/18/2003 | WO2003103624A1 Method and composition for improving sensory characteristics of semisolid predominantly anhydrous |
| 12/18/2003 | WO2003103603A2 Novel formate salt of o-desmethyl-venlafaxine |
| 12/18/2003 | WO2003103596A2 Stabilized nanoparticle formulations of camptotheca derivatives |
| 12/18/2003 | WO2003103594A2 Micelle assemblies |
| 12/18/2003 | WO2003103592A2 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use |
| 12/18/2003 | WO2003103585A2 Methods of treating angiogenesis, tumor growth, and metastasis |
| 12/18/2003 | WO2003103576A2 Reconstitutable compositions of biodegradable block copolymers |
| 12/18/2003 | WO2003103389A2 Cryopreservation of haptenized tumor cells |
| 12/18/2003 | WO2003086267A3 Multi-phase, multi-compartment capsular system |
| 12/18/2003 | WO2003082242A3 Highly aqueous liquid carrier formulations |
| 12/18/2003 | WO2003082019A3 Peptides with anti-hypertensive properties |
| 12/18/2003 | WO2003079991A3 Method for administration of growth hormone via pulmonary delivery |
| 12/18/2003 | WO2003074474A3 Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| 12/18/2003 | WO2003074090A3 Compositions of polymers |
| 12/18/2003 | WO2003074027A3 Self emulsifying drug delivery systems for poorly soluble drugs |
| 12/18/2003 | WO2003068246A3 Improvements in or relating to compositions |
| 12/18/2003 | WO2003061633B1 Non-gelatin capsule shell formulation comprising iota-carrageenan and kappa-carrageenan |
| 12/18/2003 | WO2003059988A3 Biodegradable polyketal polymers and methods for their formation and use |
| 12/18/2003 | WO2003059329A3 Polytartrate composition |
| 12/18/2003 | WO2003057135A3 Aqueous compositions containing metronidazole |
| 12/18/2003 | WO2003053431A3 Pharmaceutical compositions based on azetidine derivatives |
| 12/18/2003 | WO2003051907A3 Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells |
| 12/18/2003 | WO2003051297A3 Aqueous ifosfamide composition |
| 12/18/2003 | WO2003047511A3 Use of gingko biloba extracts to promote neuroprotection and reduce weight loss |
| 12/18/2003 | WO2003045308A3 Formulations for use in medical or diagnostic procedures |
| 12/18/2003 | WO2003044080A8 Water-in-silicone emulsions |
| 12/18/2003 | WO2003039444B1 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases |
| 12/18/2003 | WO2003022210A3 Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith |
| 12/18/2003 | WO2003012039A3 Targeting nucleic acids to a cellular nucleus |
| 12/18/2003 | WO2003009817B1 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 12/18/2003 | WO2002083030A3 Bifunctional energy-reversible acyl-compositions |
| 12/18/2003 | WO2002067916A3 Pharmaceutical salts |
| 12/18/2003 | WO2002041883A3 As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation |
| 12/18/2003 | WO2002032435A9 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 12/18/2003 | WO2002017878A8 Lung surfactant compositions with dynamic swelling behaviour |
| 12/18/2003 | US20030232971 Tumour necrosis factor binding ligands |